IDRI and Medicago to present H5N1 vaccine data at the World Vaccine Congress

IDRI (Infectious Disease Research Institute) and Medicago Inc. have announced that they will be presenting positive interim Phase I clinical results of their H5N1 Avian Influenza VLP (Virus-Like Particles) vaccine candidate at the upcoming World Vaccine Congress, Washington DC. In the presentation, titled “H5N1 Phase 1 clinical trial combining Medicago’s VLP vaccine with IDRI’s GLA adjuvant formulation,” Dr Steven Reed, …